At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 26 enrolled
Drug / intervention
Posoleucel (ALVR105)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
In Brief
A Phase 3 clinical trial evaluating Posoleucel (ALVR105) for Adenovirus Infection and 5 related conditions. Completed, enrolled 26 participants across 16 sites.
Detailed Summary
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJan 2021
Primary CompletionJan 2023
TodayJul 2026
First PostedJan 5, 2021
Enrollment StartJan 15, 2021
Primary CompletionJan 19, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.5 years ago
Interventions
Posoleucel (ALVR105)biological
Administered as 2-4 milliliter infusion